EGFR-Inhibitoren und Multityrosinkinaseinhibitoren

Zusammenfassung

Molekular zielgerichtete Therapeutika und hier insbesondere die Inhibitoren des epidermalen Wachstumsfaktorrezeptors (EGFRi) und Multityrosinkinase-Inhibitoren (MTKi) gewinnen einen immer größeren Stellenwert in der onkologischen Therapie. Die Nebenwirkungen unterscheiden sich deutlich von denen der konventionellen Chemotherapie. Vor allem kutane Nebenwirkungen stellen dosis- oder therapielimitierende Ereignisse dar. Eine genaue Kenntnis der Nebenwirkungen sowie ein enger Austausch des Dermatologen mit dem behandelnden Onkologen und dem Hausarzt, eine detaillierte Patientenaufklärung und ein fundiertes Nebenwirkungsmanagement sind Grundbausteine für eine erfolgreiche Therapie mit EGFRi und MTKi. Gemeinsame dermatologische und onkologische Schwerpunktsprechstunden helfen bei der Behandlung von schweren Fällen kutaner Toxizitäten, der Entwicklung von neuen Therapiestrategien und sind insbesondere zur Begleitbehandlung von Patienten in klinischen Studien essentiell.

Abstract

Molecular targeted therapies – particularly epidermal growth factor receptor inhibitors (EGFRi) and multi tyrosine kinase-inhibitors (MTKi) – continually gain importance in oncology treatment. Adverse events differ greatly from those of conventional chemotherapy; especially cutaneous adverse events often constitute dose-limiting or therapy-limiting events. Knowledge of possible adverse events and close interaction between the dermatologist, the oncologist and the patient’s family physician, a detailed patient education and a well-founded adverse event management are mandatory for the treatment with EGFRi and MTKi. Interdisciplinary outpatient clinics specialised on the treatment of these adverse events assist with the treatment of severe cases, the development of new therapeutic strategies and are essential for the concomitant treatment of patients treated with new targeted drugs within clinical trials.

Schlüsselwörter

EGFRi - MTKi - Tyrosinkinaseinhibitoren - kutane Nebenwirkungen - targeted therapy - Nebenwirkungsmanagement

Keywords

EGFRi - MTKi - tyrosinkinase inhibitors - cutaneous adverse events - targeted therapy - adverse event management

Literatur

• 1 Arnault J P, Wechsler J, Escudier B, Spatz A, Tomasic G, Sibaud V, Aractingi S, Grange J D, Poirier-Colame V, Malka D, Soria J C, Mateus C, Robert C. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.  J Clin Oncol. 2009;  27 e59-61
• 2 Boone S L, Rademaker A, Liu D, Pfeiffer C, Mauro D J, Lacouture M E. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.  Oncology. 2007;  72 152-159
• 3 Chou L S, Garey J, Oishi K, Kim E. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.  Clin Lung Cancer. 2006;  8, Suppl 1 S15-22
• 4 Cortesi E, DePasquale C, D’Auria G. et al . Management of cutaneous adverse effects during treatment with ZD1838 in advanced non-small cell lung cancer (NSCLC): surprising efficacy of early local treatment.  Proc Am Assoc Cancer Res. 2004;  22 abstr 7100
• 5 Dancey J, Sausville E A. Issues and progress with protein kinase inhibitors for cancer treatment.  Nat Rev Drug Discov. 2007;  2 296-313
• 6 Dasanu C A, Alexandrescu D T, Dutcher J. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.  South Med J. 2007;  100 328-330
• 7 Degen A, Alter M, Schenck F, Satzger I, Volker B, Kapp A, Gutzmer R. The hand-foot-syndrome associated with medical tumor therapy – classification and management.  J Dtsch Dermatol Ges. 2010;  8 652-661
• 8 Dubauskas Z, Kunishige J, Prieto V G, Jonasch E, Hwu P, Tannir N M. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.  Clin Genitourin Cancer. 2009;  7 20-23
• 9 Eilers Jr R E, Gandhi M, Patel J D, Mulcahy M F, Agulnik M, Hensing T, Lacouture M E. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.  J Natl Cancer Inst. 2010;  102 47-53
• 10 Eiling E, Brandt M, Schwarz T, Hauschild A. Pimecrolimus: a novel treatment for cetuximab-induced papulopustular eruption.  Arch Dermatol. 2008;  144 1236-1238
• 11 Fox L P. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy.  J Am Acad Dermatol. 2007;  56 460-465
• 12 Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J Y, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong R P, Baselga J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].  J Clin Oncol. 2003;  21 2237-2246
• 13 Golub L M, Lee H M, Ryan M E, Giannobile W V, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms.  Adv Dent Res. 1998;  12 12-26
• 14 Grandinetti C A, Goldspiel B R. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.  Pharmacotherapy. 2007;  27 1125-1144
• 15 Hong D S, Reddy S B, Prieto V G, Wright J J, Tannir N M, Cohen P R, Diwan A H, Evans H L, Kurzrock R. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.  Arch Dermatol. 2008;  144 779-782
• 16 Hu J C, Sadeghi P, Pinter-Brown L C, Yashar S, Chiu M W. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.  J Am Acad Dermatol. 2007;  56 317-326
• 17 Jantzem H, Dupre-Goetghebeur D, Spindler P, Merrer J. [Sorafenib-induced multiple eruptive keratoacanthomas].  Ann Dermatol Venereol. 2009;  136 894-897
• 18 Jatoi A, Rowland K, Sloan J A, Gross H M, Fishkin P A, Kahanic S P, Novotny P J, Schaefer P L, Johnson D B, Tschetter L K, Loprinzi C L. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).  Cancer. 2008;  113 847-853
• 19 Kong H H, Cowen E W, Azad N S, Dahut W, Gutierrez M, Turner M L. Keratoacanthomas associated with sorafenib therapy.  J Am Acad Dermatol. 2007;  56 171-172
• 20 Krakauer T, Buckley M. Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines.  Antimicrob Agents Chemother. 2003;  47 3630-3633
• 21 Kwon E J, Kish L S, Jaworsky C. The histologic spectrum of epithelial neoplasms induced by sorafenib.  J Am Acad Dermatol. 2009;  61 522-527
• 22 Lacouture M E. Mechanisms of cutaneous toxicities to EGFR inhibitors.  Nat Rev Cancer. 2006;  6 803-812
• 23 Lacouture M E, Basti S, Patel J, Benson A. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors.  J Support Oncol. 2006;  4 236-238
• 24 Lacouture M E, Boerner S A, Lorusso P M. Non-rash skin toxicities associated with novel targeted therapies.  Clin Lung Cancer. 2006;  8 Suppl 1 S36-42
• 25 Lacouture M E, Desai A, Soltani K, Petronic-Rosic V, Laumann A E, Ratain M J, Stadler W M. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.  Clin Exp Dermatol. 2007;  31 783-785
• 26 Lacouture M E, Melosky B L. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.  Skin Therapy Lett. 2007;  12 1-5
• 27 Lacouture M E, Wu S, Robert C, Atkins M B, Kong H H, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu D T, Anderson R T, Wood L, Dutcher J P. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.  Oncologist. 2008;  13 1001-1011
• 28 Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors.  Target Oncol. 2009;  4 107-119
• 29 LoRusso P. Toward evidence-based management of the dermatologic effects of EGFR inhibitors.  Oncology (Williston Park). 2009;  23 186-194
• 30 Marquez C B, Smithberger E E, Bair S M, Wenham R M, Fenske N A, Glass L F, Cherpelis B S. Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.  Cancer Control. 2009;  16 66-69
• 31 Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations.  Curr Oncol. 2009;  16 16-26
• 32 Mitchell E P, Lacouture M, Shearer H. et al . Updated results of STEPP, a phase 2, open-label study of pre-emptive versus reactive skin toxicity treatment in metastatic colorectal cancer (mCRC) patients receiving panitumumab+ FOLFIRI or irinotecan-only chemotherapy as second-line treatment.  Ann Oncol. 2008;  19 (suppl) O-021
• 33 Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?.  Oncology (Williston Park). 2003;  17 23-28
• 34 Perez-Soler R, Chachoua A, Hammond L A, Rowinsky E K, Huberman M, Karp D, Rigas J, Clark G M, Santabarbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non – small-cell lung cancer.  J Clin Oncol. 2003;  22 3238-3247
• 35 Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?.  J Clin Oncol. 2005;  23 5235-5246
• 36 Perez-Soler R, Zou Y, Li T. et al . Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin.  J Clin Oncol. 2003;  24 3036a
• 37 Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents.  The case of sorafenib and sunitinib Clin Exp Med. 2007;  7 127-134
• 38 Potthoff K, Hofheinz R, Hassel J C, Volkenandt M, Lordick F, Hartmann J T, Karthaus M, Riess H, Lipp H P, Hauschild A, Trarbach T, Wollenberg A. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.  Ann Oncol. 2010;  [Epub ahead of print]
• 39 Robert C, Soria J C, Spatz A, Le Cesne  A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand J P, Le Chevalier T. Cutaneous side-effects of kinase inhibitors and blocking antibodies.  Lancet Oncol. 2005;  6 491-500
• 40 Roe E, Garcia Muret M P, Marcuello E, Capdevila J, Pallares C, Alomar A. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.  J Am Acad Dermatol. 2006;  55 429-437
• 41 Scope A, Agero A L, Dusza S W, Myskowski P L, Lieb J A, Saltz L, Kemeny N E, Halpern A C. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.  J Clin Oncol. 2007;  25 5390-5396
• 42 Segaert S, Tabernero J, Chosidow O, Dirschka T, Elsner J, Mancini L, Maughan T, Morere J F, Santoro A, Sobrero A, Van Cutsem E, Layton A. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.  J Dtsch Dermatol Ges. 2005;  3 599-606
• 43 Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.  Ann Oncol. 2005;  16 1425-1433
• 44 Smith K J, Haley H, Hamza S, Skelton H G. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.  Dermatol Surg. 2009;  35 1766-1770
• 45 Tsao A S, Kantarjian H, Cortes J, O’Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin.  Cancer. 2003;  98 2483-2487
• 46 Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, Tulliez M, Giraudier S. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.  J Am Acad Dermatol. 2003;  48 201-206
• 47 Wollenberg A, Kroth J, Hauschild A, Dirschka T. Hautreaktionen unter EGFR-Inhibitoren – Klinik und Management.  Dtsch Med Wochenschr. 2010;  135 149-154